Point72 Hong Kong’s Cullinan Oncology CGEM Stock Holding History

Point72 Hong Kong’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-929	Closed	-$14K	–	1891
2021 Q4	$14K	Buy	+929	New	+$18.5K	﹤0.01%	1592

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Point72 Hong Kong's CGEM Position: Q1 2022 in Review

Point72 Hong Kong sold out of Cullinan Oncology (CGEM) in Q1 2022, closing a stake of 929 shares — an estimated $14K sold.

Point72 Hong Kong first reported a position in CGEM in Q4 2021 and held it in 1 quarter. The position peaked at $14K in Q4 2021. 82 funds tracked by Wall St. Rank hold CGEM as of Q1 2022.

Point72 Hong Kong reported no remaining Cullinan Oncology position as of Q1 2022 after selling out during the quarter.
Point72 Hong Kong sold 929 Cullinan Oncology shares in Q1 2022, an estimated $14K.
Point72 Hong Kong first reported a position in Cullinan Oncology in Q4 2021 and held it in 1 quarter.
Point72 Hong Kong's Cullinan Oncology position peaked at $14K in Q4 2021.
82 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2022.

Based on Point72 Hong Kong's 13F filing for Q1 2022, filed 16 May 2022.